Trial Registered

Createrna's QR12000 completes Phase 2 hypertension trial, results not yet posted

The 391-patient trial closed in September 2023 with a blood-pressure primary endpoint, but ClinicalTrials.gov carries no posted result data on the readout.

By AppliedXLJuly 14, 2026Trial NCT07700875

Executive Summary

A Phase 2 study of Wuhan Createrna's QR12000 compound tablets in patients with moderate to severe essential hypertension completed enrollment to target and closed out its primary follow-up period without any registered protocol disruption.
The trial was built to measure blood pressure reduction against baseline at an early time point, the standard bar for early antihypertensive development, in a population whose disease had already proven resistant to at least one prior medication regimen.
Essential hypertension is served by a large field of approved small-molecule combination therapies, and QR12000 enters that field without a disclosed mechanism that distinguishes it from established comparators.
The compound's next-stage prospects depend on how its measured blood pressure reduction compares to the established response threshold for combination antihypertensive therapy, a result that has not yet surfaced on the public registry.

The trial

The trial, registered as NCT07700875, enrolled 391 patients with moderate to severe essential hypertension starting December 29, 2022, and reached its primary completion date on August 20, 2023. ClinicalTrials.gov lists the overall study completion date as September 11, 2023, and the trial's status as Completed. The registry record for the study was added on July 14, 2026. Enrollment reached its full target of 391 patients, and the trial ran in China across a single site network. NCT07700875+1

The design

The primary endpoint measured the change from baseline in mean sitting systolic blood pressure at Week 8, evaluated against a placebo run-in comparator built into the protocol. Secondary measures tracked ambulatory systolic and diastolic pressure, diastolic pressure over time, and the proportion of patients achieving a defined blood pressure response, defined as sitting systolic pressure under 140 mmHg or a 20 mmHg reduction from baseline, combined with a diastolic pressure under 90 mmHg or a 10 mmHg reduction. Enrolled patients had msSBP above 140 mmHg or msDBP above 90 mmHg at screening, rising to a moderate-to-severe threshold of 160-190 mmHg systolic or 100-120 mmHg diastolic at baseline after a placebo run-in period that washed out prior antihypertensive medication. NCT07700875

No posted result

ClinicalTrials.gov shows no results have been posted for this trial. The registry event that triggered this record is an add-study action rather than a results submission, so the completed trial's primary blood-pressure finding is not yet public. NCT07700875+1

The field

Essential hypertension carries 165 trials that have tested small-molecule agents, a modality already dominated by generic and branded combination drugs including valsartan, amlodipine, and sacubitril/valsartan formulations, several of which are active in Phase 3 or Phase 4 studies in the same indication. QR12000's target and mechanism are not characterized in the data available, so no direct comparator sharing its target or mechanism class can be identified; the closest competitors identified share only the indication and small-molecule modality, not a common target. Given how established the small-molecule antihypertensive class already is, a blood pressure reduction at Week 8 that clears the response threshold built into the trial's own secondary endpoint would be the result that supports moving QR12000 forward.

Sponsor context

Wuhan Createrna Science and Technology Co., Ltd has completed 6 of 6 prior trials across its portfolio, with no terminations on record, and runs 14 total trials including this one. QR12000 has one registered trial to date, this Phase 2 study, with no other programs for the compound listed. The trial's protocol history shows no amendments and a stable registry pattern, consistent with a study that ran to its planned completion without operational disruption. NCT07700875

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.